Australia
Myrio Tx, founded in 2009, is positioned to make significant strides in the field of immuno-oncology with its pioneering approach to pMHC Antibody Discovery. The company is advancing antibody-based therapies to target previously elusive intracellular cancer and viral proteins. By utilizing the body's protein-breakdown and display mechanism, Myrio Tx aims to enhance the targeting of peptide-MHC complexes, potentially increasing the range of addressable cancer or viral targets tenfold.
The technology behind Myrio Tx enables the rapid generation of high-affinity and selective antibody fragments, allowing for swift evaluation and optimization of therapeutics aimed at innovative treatment modalities like CAR-T cells and antibody-drug conjugates. The company is actively pursuing collaborations to maximize its platform's capabilities while simultaneously constructing an internal product portfolio.
This cutting-edge approach positions Myrio Tx as an attractive prospect for investors interested in transformative cancer therapies.
